Patents by Inventor Jon Christopher Loren

Jon Christopher Loren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS
    Publication number: 20220340573
    Abstract: Provided herein are compounds and pharmaceutical compositions useful for treating meibomian gland dysfunction (MGD), comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a compound of Formula (I?), or pharmaceutical composition described herein.
    Type: Application
    Filed: June 6, 2022
    Publication date: October 27, 2022
    Inventors: Kelly D. BOSS, Yi FAN, Alec Nathanson FLYER, Declan HARDY, Zhihong HUANG, Kathryn Taylor LINKENS, Jon Christopher LOREN, Fupeng MA, Valentina MOLTENI, Duncan SHAW, Jeffrey SMITH, Catherine Fooks SOLOVAY
  • 1,2,4-oxadiazole derivatives as liver X receptor agonists
    Patent number: 11427586
    Abstract: Provided herein are compounds and pharmaceutical compositions useful for treating meibomian gland dysfunction (MGD), comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a compound of Formula (I?), or pharmaceutical composition described herein.
    Type: Grant
    Filed: November 23, 2020
    Date of Patent: August 30, 2022
    Assignee: NOVARTIS AG
    Inventors: Kelly D. Boss, Yi Fan, Alec Nathanson Flyer, Declan Hardy, Zhihong Huang, Kathryn Taylor Linkens, Jon Christopher Loren, Fupeng Ma, Valentina Molteni, Duncan Shaw, Jeffrey Smith, Catherine Fooks Solovay
  • 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS
    Publication number: 20220064164
    Abstract: Provided herein are compounds and pharmaceutical compositions useful for treating meibomian gland dysfunction (MGD), comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a compound of Formula (I?), or pharmaceutical composition described herein.
    Type: Application
    Filed: November 23, 2020
    Publication date: March 3, 2022
    Inventors: Kelly D. BOSS, Yi FAN, Alec Nathanson FLYER, Declan HARDY, Zhihong HUANG, Kathryn Taylor LINKENS, Jon Christopher LOREN, Fupeng MA, Valentina MOLTENI, Duncan SHAW, Jeffrey SMITH, Catherine Fooks SOLOVAY
  • Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
    Patent number: 9751876
    Abstract: Bicyclic heterocyclic derivatives of formula I useful in inhibiting PDGF receptor mediated biological activity. wherein A is and R1, R1a, R2, R3, R4, R5, R6 and X are as defined herein.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: September 5, 2017
    Assignee: Novartis AG
    Inventors: Ian Bruce, Sylvie Chamoin, Stephen Paul Collingwood, Pascal Furet, Vikki Furminger, Diana Janus, Sarah Lewis, Jon Christopher Loren, Valentina Molteni, Alex Michael Saunders, Duncan Shaw, Lilya Sviridenko, Christopher Thomson, Ryan West, Vince Yeh
  • Salt forms of bicyclic heterocyclic derivatives
    Patent number: 9073921
    Abstract: The present invention provides novel solid forms of pharmaceutically active agents and therapeutic uses thereof. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: July 7, 2015
    Assignee: Novartis AG
    Inventors: Ian Bruce, Sylvie Chamoin, Stephen Paul Collingwood, Pascal Furet, Vikki Furminger, Sarah Lewis, Jon Christopher Loren, Lin Lv, Valentina Molten, Alex Michael Saunders, Duncan Shaw, Roy Maxwell Turner, Vince Yeh
  • BICYCLIC HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
    Publication number: 20150025059
    Abstract: Bicyclic heterocyclic derivatives of formula I useful in inhibiting PDGF receptor mediated biological activity. wherein A is and R1, R1a, R2, R3, R4, R5, R6 and X are as defined herein.
    Type: Application
    Filed: October 9, 2014
    Publication date: January 22, 2015
    Applicant: Novartis AG
    Inventors: Ian Bruce, Sylvie Chamoin, Stephen Paul Collingswood, Pascal Furet, Vikki Furminger, Diana Janus, Sarah Lewis, Jon Christopher Loren, Valentina Molteni, Alex Michael Saunders, Duncan Shaw, Lilya Sviridenko, Christopher Thomson, Ryan West, Vince Yeh
  • Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
    Patent number: 8883819
    Abstract: Bicyclic heterocyclic derivatives of formula I useful in inhibiting PDGF receptor mediated biological activity. wherein A is and R1, R1a, R2, R3, R4, R5, R6 and X are as defined herein.
    Type: Grant
    Filed: August 30, 2012
    Date of Patent: November 11, 2014
    Assignees: IRM LLC, Novartis AG
    Inventors: Ian Bruce, Sylvie Chamoin, Stephen Paul Collingwood, Pascal Furet, Vikki Furminger, Diana Janus, Sarah Lewis, Jon Christopher Loren, Valentia Molteni, Alex Michael Saunders, Duncan Shaw, Lilya Sviridenko, Christopher Thomson, Ryan West, Vince Yeh
  • SALT FORMS OF BICYCLIC HETEROCYCLIC DERIVATIVES
    Publication number: 20140249177
    Abstract: The present invention provides novel solid forms of pharmaceutically active agents and therapeutic uses thereof. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: February 21, 2014
    Publication date: September 4, 2014
    Applicant: NOVARTIS AG
    Inventors: Ian BRUCE, Sylvie CHAMOIN, Stephen Paul COLLINGWOOD, Pascal FURET, Vikki FURMINGER, Sarah LEWIS, Jon Christopher LOREN, Lin LV, Valentina MOLTEN, Alex Michael SAUNDERS, Duncan SHAW, Roy Maxwell TURNER, Vince YEH
  • BICYCLIC HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
    Publication number: 20130237519
    Abstract: Bicyclic heterocyclic derivatives of formula I useful in inhibiting PDGF receptor mediated biological activity. wherein A is and R1, R1a, R2, R3, R4, R5, R6 and X are as defined herein.
    Type: Application
    Filed: August 30, 2012
    Publication date: September 12, 2013
    Inventors: Ian Bruce, Sylvie Chamoin, Stephen Paul Collingwood, Pascal Furet, Vikki Furminger, Diana Janus, Sarah Lewis, Jon Christopher Loren, Valentina Molteni, Alex Michael Saunders, Duncan Shaw, Lilya Sviridenko, Christopher Thomson, Ryan West, Vince Yeh